The stock's fall snapped a two-day winning streak.

EST Ocugen (OCGN) files to sell 57.54M shares of common stock for holdersInvest with Confidence: Follow TipRanks' Top Wall Street ...

This was the stock's second consecutive day of gains.

Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has ...

Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.73 which represents a decrease of $-0.05 or -6.41% from the prior close of $0.78. The stock opened at $0.78 and touched a low of $0.71 ...

Ocugen (OCGN) announced that the U.S. FDA has reviewed the company’s Investigational New Drug application and it is in effect. This is a ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

MALVERN, PA, USA I January 16, 2025 I Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell ...

Ocugen aims for OCU200 to be a first-line therapy for DME, diabetic retinopathy, and wet AMD, benefiting patients unresponsive to current treatments. The phase 1 clinical trial is a multicenter, ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing ...

Ocugen, Inc. has announced the commencement of its Phase 1 clinical trial for OCU200, targeting diabetic macular edema (DME). The trial, which has begun dosing its first patient, aims to evaluate ...